{"id":"fulvestrant-injection-dalpiciclib-isethionate","safety":{"commonSideEffects":[{"rate":null,"effect":"Neutropenia"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Hot flashes"},{"rate":null,"effect":"Injection site reactions"}]},"_chembl":{"chemblId":"CHEMBL2364621","moleculeType":"Small molecule","molecularWeight":"573.68"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Fulvestrant is a selective estrogen receptor degrader (SERD) that binds to and degrades estrogen receptors, eliminating their function in hormone receptor-positive breast cancer. Dalpiciclib is a CDK4/6 inhibitor that prevents the phosphorylation of retinoblastoma protein, blocking G1/S cell cycle transition. Together, they provide complementary mechanisms to suppress proliferation of hormone-sensitive breast cancer cells.","oneSentence":"This combination uses fulvestrant to block estrogen receptors in breast cancer cells while dalpiciclib inhibits cyclin-dependent kinases 4 and 6 to prevent cell cycle progression.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:13:32.530Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hormone receptor-positive, HER2-negative advanced or metastatic breast cancer"}]},"trialDetails":[{"nctId":"NCT07354022","phase":"PHASE3","title":"A Study to Evluate Efficacy and Safety of HRS-8080 Combined With Dalpiciclib in Patients With Advanced or Metastatic Breast Cancer Resistant to Adjuvant Endocrine Therapy.","status":"RECRUITING","sponsor":"Shandong Suncadia Medicine Co., Ltd.","startDate":"2026-03-04","conditions":"Locally Advanced or Metastatic Breast Cancer","enrollment":912},{"nctId":"NCT05792410","phase":"PHASE1, PHASE2","title":"A Phase Ⅰb/Ⅱ Clinical Study of SHR-A1811 Combined With Other Therapies in Patients With HER2 Low Advanced or Metastatic Breast Cancer.","status":"UNKNOWN","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2023-04","conditions":"HER2 Low Advanced or Metastatic Breast Cancer","enrollment":300}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Fulvestrant injection ;Dalpiciclib Isethionate","genericName":"Fulvestrant injection ;Dalpiciclib Isethionate","companyName":"Shandong Suncadia Medicine Co., Ltd.","companyId":"shandong-suncadia-medicine-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination uses fulvestrant to block estrogen receptors in breast cancer cells while dalpiciclib inhibits cyclin-dependent kinases 4 and 6 to prevent cell cycle progression. Used for Hormone receptor-positive, HER2-negative advanced or metastatic breast cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}